Cervical Pessary for Prevention of Preterm Birth in Individuals With a Short Cervix: The TOPS Randomized Clinical Trial
- PMID: 37490086
- PMCID: PMC10369212
- DOI: 10.1001/jama.2023.10812
Cervical Pessary for Prevention of Preterm Birth in Individuals With a Short Cervix: The TOPS Randomized Clinical Trial
Abstract
Importance: A short cervix as assessed by transvaginal ultrasound is an established risk factor for preterm birth. Study findings for a cervical pessary to prevent preterm delivery in singleton pregnancies with transvaginal ultrasound evidence of a short cervix have been conflicting.
Objective: To determine if cervical pessary placement decreases the risk of preterm birth or fetal death prior to 37 weeks among individuals with a short cervix.
Design, setting, and participants: We performed a multicenter, randomized, unmasked trial comparing a cervical pessary vs usual care from February 2017 through November 5, 2021, at 12 centers in the US. Study participants were nonlaboring individuals with a singleton pregnancy and a transvaginal ultrasound cervical length of 20 mm or less at gestations of 16 weeks 0 days through 23 weeks 6 days. Individuals with a prior spontaneous preterm birth were excluded.
Interventions: Participants were randomized 1:1 to receive either a cervical pessary placed by a trained clinician (n = 280) or usual care (n = 264). Use of vaginal progesterone was at the discretion of treating clinicians.
Main outcome and measures: The primary outcome was delivery or fetal death prior to 37 weeks.
Results: A total of 544 participants (64%) of a planned sample size of 850 were enrolled in the study (mean age, 29.5 years [SD, 6 years]). Following the third interim analysis, study recruitment was stopped due to concern for fetal or neonatal/infant death as well as for futility. Baseline characteristics were balanced between participants randomized to pessary and those randomized to usual care; 98.9% received vaginal progesterone. In an as-randomized analysis, the primary outcome occurred in 127 participants (45.5%) randomized to pessary and 127 (45.6%) randomized to usual care (relative risk, 1.00; 95% CI, 0.83-1.20). Fetal or neonatal/infant death occurred in 13.3% of those randomized to receive a pessary and in 6.8% of those randomized to receive usual care (relative risk, 1.94; 95% CI, 1.13-3.32).
Conclusions and relevance: Cervical pessary in nonlaboring individuals with a singleton gestation and with a cervical length of 20 mm or less did not decrease the risk of preterm birth and was associated with a higher rate of fetal or neonatal/infant mortality.
Trial registration: ClinicalTrials.gov Identifier: NCT02901626.
Conflict of interest statement
Figures


Comment in
-
The Vexing Problem of Preterm Birth Prevention.JAMA. 2023 Jul 25;330(4):323-325. doi: 10.1001/jama.2023.7244. JAMA. 2023. PMID: 37490098 No abstract available.
References
-
- Martin JA, Hamilton BE, Osterman MJK, Driscoll AK. Births: final data for 2019. Natl Vital Stat Rep. 2021;70(2):1-51. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- U10 HD040500/HD/NICHD NIH HHS/United States
- UG1 HD027869/HD/NICHD NIH HHS/United States
- UG1 HD087230/HD/NICHD NIH HHS/United States
- R01 DK034208/DK/NIDDK NIH HHS/United States
- U10 HD027915/HD/NICHD NIH HHS/United States
- U10 HD040512/HD/NICHD NIH HHS/United States
- U01 HD036801/HD/NICHD NIH HHS/United States
- U10 HD034208/HD/NICHD NIH HHS/United States
- UG1 HD027915/HD/NICHD NIH HHS/United States
- UG1 HD087192/HD/NICHD NIH HHS/United States
- UG1 HD040544/HD/NICHD NIH HHS/United States
- UG1 HD034208/HD/NICHD NIH HHS/United States
- UG1 HD040512/HD/NICHD NIH HHS/United States
- U10 HD040545/HD/NICHD NIH HHS/United States
- U10 HD040560/HD/NICHD NIH HHS/United States
- UG1 HD040500/HD/NICHD NIH HHS/United States
- L30 MH087192/MH/NIMH NIH HHS/United States
- U24 HD036801/HD/NICHD NIH HHS/United States
- U10 HD040485/HD/NICHD NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical